-
Viatris Q4 and Full-Year Results Show Greater China Growth
•
US generics giant Viatris (NASDAQ: VTRS) released its Q4 and full-year 2024 financial results. In the fourth quarter, revenues dropped 7% year-on-year (YOY) to USD 3.515 billion. However, the Greater China region generated USD 522 million in sales after a 2% expansion. For the whole year, company revenues stood at…
-
Viatris Reports Q3 2024 Global Sales of USD 3.8 Billion with a 5% YOY Decline
•
US generics giant Viatris (NASDAQ: VTRS) has published its financial report for the third quarter of 2024, revealing a 5% year-on-year (YOY) decrease in global sales to USD 3.8 billion in constant currency terms. The report indicates that generics and brand sales fell by 2% and 6% respectively, reaching USD…
-
Lexicon Pharmaceuticals Strikes Licensing Deal with Viatris for Global Expansion of Sotagliflozin
•
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has entered into a licensing agreement with Viatris Inc. (NASDAQ: VTRS), a deal that extends Viatris’s exclusive commercialization rights to sotagliflozin in all markets outside the United States and Europe across all indications. Lexicon Pharmaceuticals retains the exclusive rights to commercialize sotagliflozin within the US…
-
Alibaba Health Forges Strategic Partnerships with Viatris and Chinese Pharma Companies for Digital Health Expansion
•
Alibaba Health Information Technology Ltd (HKG: 0241), the health industry arm of Chinese e-commerce giant Alibaba Group, has announced strategic collaboration agreements with a consortium of pharmaceutical companies. The collaborations include US-based Viatris (NASDAQ: VTRS) and Chinese firms Qilu Pharmaceutical, Chongqing Taiji Industry (Group) Co., Ltd (SHA: 600129), Shandong Dyne…
-
Viatris Launches First-of-Its-Kind Nasal Spray Dymista in China for Allergic Rhinitis
•
Viatris Inc. (NASDAQ: VTRS), a leading global pharmaceutical company based in the U.S., has announced the official launch of its nasal spray combination therapy, Dymista (azelastine, fluticasone), in China. This medication is now available to treat moderate to severe seasonal and perennial allergic rhinitis in adults and children aged 12…
-
Viatris Inc. Reports 2% Operational Growth in Q2’24, Driven by Generics and Brands
•
Viatris Inc. has announced its financial results for the second quarter of 2024, highlighting approximately 2% operational growth, reaching net revenues of USD 3.8 billion. Both the generics and brands segments experienced a rise of about 2% each during the quarter. The company also reported new product revenues amounting to…
-
Viatris Q1 2024 Results Show Slight Dip in Base Business Brands Amid Overall Stabilization
•
US pharmaceutical company Viatris (NASDAQ: VTRS) has reported its financial results for the first quarter of 2024, with global net sales remaining flat year-on-year (YOY) at USD 3.7 billion in constant currency terms. The base business brands experienced a 2% YOY decline to USD 2.3 billion, attributed to unfavorable channel…
-
Viatris Launches Ryzumvi in the US for Rapid Reversal of Pharmacologically-Induced Pupil Dilation
•
Viatris Inc. (NASDAQ: VTRS) has launched its alpha-adrenergic blocker Ryzumvi (phentolamine) in the US market, targeting the reversal of pharmacologically-induced pupil dilation caused by adrenergic agonists or parasympatholytic agents. The ophthalmic solution, which received regulatory approval last year, demonstrated in clinical trials that it could reverse eye dilation within 90…
-
Dr. Reddy’s Launches Biosimilar Versavo in UK to Challenge Roche’s Cancer Therapy Avastin
•
Dr. Reddy’s Laboratories (NYSE: RDY), a prominent Indian pharmaceutical company, has launched its biosimilar Versavo (bevacizumab) in the UK market, presenting a challenge to Roche’s established cancer therapy Avastin. Versavo, a biosimilar to Avastin, has been approved for the treatment of various metastatic cancers, including colorectal cancer, non-squamous non-small cell…
-
Viatris Secures Late-Stage Programs from Idorsia with Potential for Future Asset Additions
•
US pharmaceutical company Viatris (NASDAQ: VTRS) has entered into a licensing agreement with Swiss drugmaker Idorsia (SWX: IDIA), in-licensing two late-stage programs with the option to add two more innovative assets in the future. Viatris will pay Idorsia an upfront fee of USD 350 million, along with potential milestone payments…
-
Viatris Eyes Growth After Concluding Initial Phase of Strategy with 2023 Sales at $15.4 Billion
•
US generics giant Viatris (NASDAQ: VTRS) reported a 4% year-on-year decline in global sales to USD 15.4 billion in constant currency terms, as detailed in the company’s 2023 financial report. Despite the dip, company president Rajiv Malik declared the completion of the first phase of Viatris’s strategic plan, with the…
-
Viatris Inc. Reports Q3 2023 Global Net Sales Growth of 1% and Highlights from Earnings Call
•
US-based generics giant Viatris Inc., (NASDAQ: VTRS) has released its financial results for the third quarter of 2023. The company reported global net sales of USD 3.93 billion, marking a 1% year-on-year (YOY) increase in constant currency terms. Geographical Sales BreakdownViatris Inc.’s sales performance varied by region. Developed and Emerging…
-
Viatris to Divest Women’s Health and API Businesses, Offloading 12 Factories and 6,000 Employees
•
US-based Viatris Inc. (NASDAQ: VTRS) is set to divest its women’s health business, API operations in India, and several non-core market commercialization rights through transactions with Upjohn. This strategic move will involve the offloading of 12 factories and approximately 6,000 employees, representing 15% of the company’s global workforce. Significant Financial…
-
Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna
•
US-based Viatris Inc., (NASDAQ: VTRS) has announced that the US Food and Drug Administration (FDA) has approved the company’s Abbreviated New Drug Application (ANDA) for Breyna (budesonide + formoterol fumarate dihydrate), a generic version of AstraZeneca’s originator product Symbicort. This approval positions Viatris as the first company to offer an…
-
Viatris Reports Q4 2022 Results, Highlights China Growth
•
US-based generics giant Viatris Inc. (NASDAQ: VTRS) has released its Q4 2022 financial report. The firm reported a 2% year-on-year (YOY) fall in net sales to USD 16.2 billion. The decrease was partly attributed to the USD 3 billion sale of Viatris’ biosimilars business to India-based Biocon Biologics Ltd, a…
-
NMPA Approves Viatris’ Symfi Lo for HIV-1 Treatment in China
•
The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi Lo (efavirenz, lamivudine, tenofovir) has been approved for marketing in China. The drug was awarded priority review status in May 2020 for use in human immunodeficiency virus type 1 (HIV-1) infection in adults and children…
-
Viatris Pharmaceuticals’ HIV/AIDS Drug Prioritized for CDE Review
•
The Center for Drug Evaluation (CDE) has indicated that Viatris Pharmaceuticals Co., Ltd’s efavirenz/lamivudine/tenofovir is set for prioritized review. The drug is used to treat HIV/AIDS, combining three active ingredients to target viral replication. Drug Profile Global ApprovalsThe compound is marketed abroad under two single-dose regimes:
